www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 63), pp: 106454-106467 Research Paper Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer Andric C. Perez-Ortiz1,2, Israel Ramírez1, Juan C. Cruz-López3,*, Cynthia Villarreal- Garza4,*, Alexandra Luna-Angulo5, Esmeralda Lira-Romero1, Salvador Jiménez- Chaidez1, José Díaz-Chávez6, Juan A. Matus-Santos6, Laura Sánchez-Chapul5, Patricia Mendoza-Lorenzo7 and Francisco J. Estrada-Mena1 1Universidad Panamericana, Escuela de Medicina, Mexico City, Mexico 2Yale University School of Public Health, Laboratory of Epidemiology and Public Health, New Haven, CT, USA 3Hospital Regional ISSSTE Puebla and Hospital General Zona Norte SSEP Puebla, Puebla City, Mexico 4Depto. de Investigacion, Instituto Nacional de Cancerologia, Centro de Cancer de Mama, Tecnologico de Monterrey, Monterrey, Nuevo León, Mexico 5Instituto Nacional de Rehabilitación, Mexico City, Mexico 6Unidad de Investigación Biomédica en Cáncer, Instituto de Investigaciones Biomédicas, UNAM/Instituto Nacional de Cancerología, Mexico City, Mexico 7División Académica de Ciencias Básicas, Unidad Chontalpa, Universidad Juárez Autónoma de Tabasco, Tabasco, Mexico *These authors contributed equally to this work Correspondence to: Francisco J. Estrada-Mena, email:
[email protected] Keywords: pharmacogenetics; paclitaxel; breast cancer; genetic markers; single nucleotide polymorphism Received: July 27, 2017 Accepted: October 27, 2017 Published: November 15, 2017 Copyright: Perez-Ortiz et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Locally advanced breast cancer (LABC) cases have a varying five-year survival rate, mainly influenced by the tumor response to chemotherapy.